Monoclonal Antibodies Stocks
Biotechnology firms in this sector engineer laboratory-made proteins designed to mimic the immune system's ability to fight off harmful pathogens or target specific proteins on malignant cells. Revenue models center on high-margin biologic drug sales and long-term licensing agreements for proprietary antibody platforms used in oncology, immunology, and infectious disease treatments.
As of Oct 23, 2026, Monoclonal Antibodies has 63 US-listed companies worth $246B combined. The median member moved +2.5% over the past week; GMAB led among the 25 largest at +18.4% and RCUS trailed at -16.2%.
Companies in Monoclonal Antibodies
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- ARGX – argenx NV ADR, $54.9B
- GMAB – Genmab AS, $26.9B
- RGEN – Repligen Corporation, $11.3B
- SYRE – Spyre Therapeutics Inc., $8.7B
- TGTX – TG Therapeutics Inc, $8.1B
- IMVT – Immunovant Inc, $5.9B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- SRRK – Scholar Rock Holding Corp, $5.1B
- DNTH – Dianthus Therapeutics Inc., $4.3B
- RCUS – Arcus Biosciences Inc, $2.8B
- VRDN – Viridian Therapeutics Inc, $2.5B
- CLDX – Celldex Therapeutics Inc, $2.3B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- XNCR – Xencor Inc, $1.9B
- GENB – Generate Biomedicines, Inc. Common Stock, $1.8B
- ZBIO – Zenas BioPharma, Inc. Common Stock, $1.8B
- KRSA – Korsana Biosciences, Inc., $1.5B
- ANAB – AnaptysBio Inc, $1.5B
- IMCR – Immunocore Holdings Ltd, $1.5B
- OMER – Omeros Corporation, $1.2B
- BCAX – Bicara Therapeutics Inc. Common Stock, $1.2B
- SNDX – Syndax Pharmaceuticals Inc, $1.2B
- JBIO – Jade Biosciences, Inc., $853M
- FTH – Faeth Therapeutics, Inc., $733M
- AVTX – Avalo Therapeutics Inc, $728M
- ANNX – Annexon Inc, $726M
- OABI – OmniAb Inc., $663M
- CLYM – Climb Bio Inc, $592M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- STTK – Shattuck Labs Inc, $548M
- CBIO – Crescent Biopharma, Inc., $532M
- ZURA – Zura Bio Limited Class A Ordinary Shares, $396M
- RZLT – Rezolute Inc, $396M
- QTTB – Q32 Bio Inc, $232M
- PYXS – Pyxis Oncology Inc, $220M
- CGEN – Compugen, $219M
- YARW – Yarrow Bioscience Inc, $183M
- IVVD – Invivyd Inc., $182M
- IPHA – Innate Pharma, $160M
- CHRS – Coherus BioSciences Inc, $156M
- VRXA – Veraxa Biotech AG Ordinary Shares, $156M
- UPB – Upstream Bio, Inc., $151M
- TLSA – Tiziana Life Sciences Ltd, $144M
- ABOS – Acumen Pharmaceuticals Inc, $143M
- OTLK – OUTLOOK THERAPEUTICS INC, $127M
- CRBP – Corbus Pharmaceuticals Holding, $85.5M
- PMN – ProMIS Neurosciences Inc., $74.3M
- XBIT – XBiotech Inc, $65.9M
- CNTB – Connect Biopharma Holdings Ltd, $56.7M
- IMA – ImageneBio, Inc., $52.4M
- EDSA – Edesa Biotech Inc, $36.1M
- ATNM – Actinium Pharmaceuticals Inc, $30.6M
- JSPR – Jasper Therapeutics Inc, $19M
- CMMB – Chemomab Therapeutics Ltd DRC, $8.4M
- SKYE – Skye Bioscience, Inc. Common Stock, $7.2M
- LIMN – Liminatus Pharma, Inc. Class A Common Stock, $5M
- VCNX – Vaccinex Inc, $2.8M
- PPBT – Purple Biotech, $2.5M
- KAPA – Kairos Pharma, Ltd., $2M
- ZVSA – ZyVersa Therapeutics Inc., $647,673
- SRNE – Sorrento Therape, $441,024
- ARDS – Aridis Pharmaceuticals Inc, $4,457